The effect of NMDA receptor antagonism on cortical gamma power and synchronization in vivo by Wilcox, Ashleigh Georgina
  
 
 
THE EFFECT OF NMDA RECEPTOR ANTAGONISM ON 
CORTICAL GAMMA POWER AND SYNCHRONISATION IN 
VIVO 
 
 
by 
ASHLEIGH GEORGINA WILCOX 
 
 
 
 
A thesis submitted to  
the University of Birmingham  
for the degree of MASTER OF RESEARCH 
 
 
 
 
 
 
 
 
 
Neurobiology Section 
School of Clinical and Experimental Medicine 
College of Medical and Dental Sciences 
University of Birmingham 
August 2014 
 
 
 
 
 
 
 
 
 
University of Birmingham Research Archive 
 
e-theses repository 
 
 
This unpublished thesis/dissertation is copyright of the author and/or third 
parties. The intellectual property rights of the author or third parties in respect 
of this work are as defined by The Copyright Designs and Patents Act 1988 or 
as modified by any successor legislation.   
 
Any use made of information contained in this thesis/dissertation must be in 
accordance with that legislation and must be properly acknowledged.  Further 
distribution or reproduction in any format is prohibited without the permission 
of the copyright holder.  
 
 
 
 - ABSTRACT - 
 
Acute administration of NMDA receptor antagonists such as PCP and ketamine are 
accepted models of schizophrenia in rats. Oscillatory activity in the gamma range (30-120 Hz) 
is known to be increased in schizophrenia and by NMDA receptor antagonism. Putative links 
have been made between abnormal gamma activity and cognitive deficits that are known in 
schizophrenia. However, the site of action of these antagonists and how they modulate 
gamma in vivo remains unclear.  
In this study PCP was systemically injected into freely moving rats and ketamine 
systemically injected into terminally anaesthetised rats, whilst recording intracranial EEG 
activity in the prefrontal cortex, visual cortex and hippocampus. Ketamine was also 
administered locally into these same areas in anaesthetised rats and EEG activity recorded.  
1 mg/kg PCP significantly decreased performance in an associative learning task, 
significantly increased gamma power in all recording areas and decreased inter-area gamma 
synchronisation. 4 mg/kg ketamine also significantly increased gamma power and decreased 
inter-area synchronisation. Local injection of 5 µg/µl ketamine caused no significant changes 
to gamma power or inter-area synchronisation.  
The data presented in this study suggests that local NMDA receptor antagonism may 
not be the primary cause of changes to gamma activity that occurs following systemic 
treatments. 
 
 
 - ACKNOWLEDGEMENTS - 
 
This project was conducted under the supervision of M. Vreugdenhil. The micro-pumps 
used in experiments in this study were supplied by S. Barker and colleagues at Boise State 
University; thanks go to them for allowing the pumps to be used in this project and for 
including us in the development of their work.  
The author would like to acknowledge the bank account of G. Wilcox & K.A. Thompson 
for funding this work. Completion of this project greatly benefitted from A.D. Powell’s 
excellent tea making skills, G. Morris’ unrivalled commitment to sticker collecting and S. 
Avazzadeh’s insistence on eating lunch at a suitable time. Also, the positive working 
environment created by everyone in Neuronal Networks who endeavoured to make the 
author’s time in the lab an enjoyable one. Finally, sincerest of thanks go to the author’s mentor 
A.J. Cooper for her continued support and advice throughout the project.  
This thesis and all work leading up to it is dedicated to Kenny, the truest friend that 
anyone could have ever hoped for. If “the only escape from the miseries of life are music and 
cats” (Albert Schweitzer), then all that is left is music which will never sound the same. 
 
 
 
 
 
 
 - CONTENTS - 
 
1. Introduction           
1.i. Schizophrenia as a cognitive disorder      1 
1.ii. The NMDAR and schizophrenia       2 
1.iii. Oscillatory activity in the brain       4 
1.iv. Aims and rationale         6 
 
2. Methods            
2.i. Freely moving animal experiments       8 
2.ii. Anaesthetised rat experiments       13 
 
3. Results            
3.i. PCP experiments in freely moving rats      21 
3.ii. Systemic ketamine experiments in anaesthetised rats    30 
3.iii. Local ketamine experiments in anaesthetised rats     38 
3.iv. Comparison of systemic and local injection of ketamine    45 
 
4. Discussion           
4.i. Acute PCP model of schizophrenia in freely moving rats    48 
4.ii. Systemic ketamine model of schizophrenia in terminally anaesthetised rats 50 
4.iii. Local application of ketamine in terminally anaesthetised rats   53 
4.iv. Concluding remarks         57 
 
5. References          58 
 
 
 
 
 - FIGURES - 
 
1. Introduction 
1.1. Non-competitive inhibition of NMDAR via the PCP binding site in the channel pore  
 
2. Methods 
2.1. Images and layout used on the touchscreen for sPAL testing of rats in behavioural 
testing chamber. 
2.2. Electrodes were constructed to facilitate recording from two different areas. 
2.3. Recording electrodes were implanted in VC, Hip and PFC to record local EEG activity. 
2.4. Guide cannulas were implanted proximally to recording electrodes. 
2.5. Insertion cannulas were implanted proximally to recording electrodes in the area of 
interest.  
 
3. Results 
3.1. Traces had to be cleaned and movement artefacts removed to leave EEG activity. 
3.2. An example of the power spectra generated for analysis of changes to power following 
PCP treatment. 
3.3. Systemic PCP injection caused an increase in gamma power in all recording areas 
throughout sPAL task completion. 
3.4. Raw traces were filtered to leave activity in the relevant frequency bands needed for 
cross correlation analysis. 
 3.5. From filtered traces in relevant frequency bands, cross-correlograms were generated 
showing the phase relationship between recording areas. 
3.6. Electrical stimulation via the pontis oralis created an active cortex which could be 
deemed a stable baseline for terminal experiments. 
3.7. Power spectra from different areas showed different distributions of power 
frequencies before and after systemic injection with ketamine. 
3.8. Gamma power was increased by systemic injection with 4 mg/kg and 10 mg/kg 
ketamine. 
3.9. Band pass filtering was used to give HFG and HFGP for cross-correlation analysis of 
terminal experiments. 
3.10. Local injection of ketamine into Hip caused percentage increases in recording areas 
when using peak gamma value but none were deemed significant. 
3.11. Local injection of dye remained in the desired injection area. 
3.12. Local injection of TTX abolished local oscillatory activity in Hip following Hip injection. 
3.13. Systemic injection of ketamine produced a different effect signature to local injection. 
3.14. Local injection of ketamine into Nucleus Basalis caused an increase in power across the 
entire gamma range. 
 
 - TABLES - 
 
3. Results 
3.1. Systemic PCP caused a decrease in inter-area LFG correlation during sPAL task 
completion. 
3.2. Systemic PCP caused a decrease in inter-area LFGP correlation during sPAL task 
completion. 
3.3. Systemic PCP caused no significant changes to slow-LFGP inter-area correlation during 
sPAL task completion. 
3.4. Systemic ketamine induced changes to inter-area LFG and HFG correlations. 
3.5. Systemic ketamine treatment increased inter-area LFGP and HFGP correlation for all 
areas. 
3.6. Systemic ketamine treatment caused significant decreases to slow-LFGP correlations 
between PrL/Cg1 and Hip but caused none for slow-HFGP correlations. 
3.7. Local injection of ketamine caused no significant changes to gamma power. 
3.8. Local injection of ketamine into PFC, Hip and VC did not significantly alter inter-area 
correlation. 
3.9. Local injection of ketamine into PFC, Hip and VC caused no clear pattern of change to 
slow-LFGP inter-area correlations. 
 
Chapter 1 | INTRODUCTION | A G Wilcox 
 
[1] 
 
- INTRODUCTION - 
 
1i | Schizophrenia as a cognitive disorder 
Schizophrenia is a serious psychiatric disorder affecting up to 1% of the population 
worldwide (Javitt, 2010). Symptoms associated with the condition are commonly separated 
into two categories: positive and negative. Positive symptoms include hallucination, hostility, 
delusions and disorganisation of thoughts. Whereas negative symptoms include anhedonia, 
withdrawal from social obligations, apathy and avolition (Jodo, 2013; Dauvermann et al, 
2014). As well as these emotional and behavioural symptoms, schizophrenic individuals also 
have well characterised deficits in cognition. The disorder is now termed as ‘widespread 
cortical dysfunction’ which accounts for the diverse range of symptoms mentioned. Often 
cognitive deficits precede official diagnosis of the disease and any true first psychotic episode, 
and will worsen throughout progression of the condition. Also, deficits in cognitive functions 
such as working memory have been found to be depleted in those at high risk of developing 
the disorder – reinforcing the importance of cognitive ability as a core component of the illness 
even before any conversion to psychosis (Dauvermann et al, 2014; Javitt, 2010).   
Through viewing schizophrenia as a condition of neuronal network dysfunction, two 
major theories of disease development were proposed - the dopaminergic and glutamatergic. 
The original dopamine hypothesis states that alterations in dopaminergic receptors underlie 
the clinical symptoms observed in schizophrenia. This theory is no longer solely believed to be 
true as it does not account for negative and cognitive symptoms, which are extremely 
important in classifying diagnoses (Howes & Kapur, 2009).  The original glutamate hypothesis 
- first proposed by JS Kim and colleagues in 1980 (Kim et al, 1980) was based on the idea that 
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alterations to glutamate receptors was the key cause of schizophrenia development. This has 
been subsequently expanded to include various other aspects of glutamatergic transmission 
to account for positive, negative and cognitive symptoms occurring in schizophrenia. There 
are also other theories that highlight the role of the serotonin system in schizophrenia 
pathology, which are originally based on interactions between LSD and the serotonin receptor 
during drug induced psychosis (Aghajanian & Marek, 2000). It is likely that no sole theory is 
true or complete, and that interactions between different systems involved in neural 
transmission account for the overall pathology of schizophrenia. However, this study was 
focussed on a key element of glutamatergic transmission: the N-methyl-D-aspartate receptor 
(NMDAR). 
  
1ii | The NMDAR and schizophrenia 
Originally, the glutamate hypothesis of schizophrenia was based on the observation 
that treatment with drugs such as ketamine and phencyclidine (PCP) mimics psychosis in 
healthy humans and animals – which is thought to be comparable to some aspects of positive 
symptoms in schizophrenia. These drugs are antagonists of the NMDAR, which is a glutamate 
receptor subtype abundant in the central nervous system (Dauvermann et al, 2014; Javitt, 
2010). Glutamate receptors mediate excitatory synaptic transmission through interactions 
with, amongst others, GABA (gamma aminobutyric acid)-ergic interneurons and dopaminergic 
neurons (Traynelis et al, 2010) and so dysfunction of this class of receptor is likely to have 
widespread cortical consequences to subsequent neuronal transmission systems. The NMDAR 
is also crucial for long-term potentiation, thus NMDAR hypofunction will lead to reduced 
reinforcement of synaptic connections and is implicated in schizophrenia development (Coyle 
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et al, 2003). NMDARs are composed of a combination of different subunits classified as NR1, 
NR2 and NR3; within these units there are various other subtypes known. For example, NR2A 
and NR2B are the dominant classes of NR2 subunit in the adult brain (Lee & Rajakumar, 2003). 
It is also thought that subunit composition may contribute to the pathology of schizophrenia 
as they convey different pharmacological properties (Cull-Candy et al, 2001). 
The NMDAR is activated via binding of glutamate along with its co-agonist glycine to 
their respective sites. Under normal circumstances, the NMDAR is blocked by Mg2+ at the Mg 
binding site on the receptor. Depolarisation above threshold in the postsynaptic cell removes 
the Mg2+ and an influx of Ca2+ occurs. Competitive inhibition of NMDAR occurs via binding to 
the glutamate or glycine binding site, thus blocking the receptor from being activated. Non-
competitive inhibition occurs via binding to a PCP binding site located in the pore of the 
receptor channel, thus blocking ion flow through the channel (figure 1.1).  
Figure 1.1| Non-competitive inhibition of NMDAR via the PCP binding site in the channel pore. 
Glutamate and glycine bind to activate the receptor at the sites indicated. Under normal 
circumstances, depolarisation of the postsynaptic cell removes Mg2+ block and Ca2+ influx occurs. 
This is unable to occur when a non-competitive antagonist such as PCP or ketamine is bound to 
the PCP binding site in the pore of the channel. Treatment with PCP or ketamine can therefore be 
used to mimic NMDAR hypofunction observed in schizophrenia.  
Chapter 1 | INTRODUCTION | A G Wilcox 
 
[4] 
 
 
Ketamine and PCP work via this non-competitive binding route to inhibit the NMDAR (Watkins, 
1994; Frohlich & Van Horn, 2013). Since NMDAR hypofunction has been implicated in 
schizophrenia, it follows that administration of a systemic injection of PCP or ketamine can be 
used to create an acute model of schizophrenia. This method was used in rats to create the 
models for this study. It should be noted that there are also developmental, genetically 
manipulated and lesion animal models of schizophrenia. No animal model is considered a 
complete recreation, as schizophrenia is a complex heterogeneous disorder, but many are 
accepted replications of particularly positive symptoms and some cognitive (Jones et al, 2011).  
 
1iii | Oscillatory activity in the brain  
 Neuronal networks create oscillatory activity that is abundant throughout cortical 
regions of the mammalian brain (Ermentrout & Chow, 2002). Changes in oscillations can be 
induced by sensory and/or cognitive events and are usually classified into ‘natural’ frequency 
ranges in the brain: alpha, theta, delta, beta and gamma (Basar et al, 2001). It has been long 
argued that these changes in rhythmic oscillatory activity have functional significance in the 
cortex. Oscillations within the gamma band (30-120 Hz) are almost continually present (Jasper 
& Andrews, 1938; Whittington et al, 2010) and occur in all cortical areas (Uhlhaas & Singer, 
2010). Gamma is continually implicated in cortical processing as oscillations in this frequency 
band become more prevalent during cognitive task completion and are known to be induced 
by sensory input to different cortical areas (Wang, 2010; Bartos, Vida & Jonas, 2007).  
Integration of information in the brain requires some level of synchrony; 
synchronisation of generated oscillations remains the most widely accepted method to 
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achieve this (Buzsaki & Draguhn, 2004; Uhlhaas & Singer, 2013). Importantly, the 
synchronisation of oscillations either between the same frequencies (e.g. gamma to gamma) 
or between different frequencies (e.g. theta to gamma) in different areas are thought to be 
responsible for communication within and between areas. This is critical for cognitive 
functions that require combination of sensory inputs from different cortical areas and for 
recall of information – i.e. in working memory. Some of the deficits stated earlier that occur 
in schizophrenia are due to reduced inter-area communication and therefore, it could be 
argued, reduced synchronisation of oscillations (Wang, 2010). One study, which analysed data 
from experiments conducted in awake cats and monkeys (Womelsdorf et al, 2007), concluded 
that gamma band synchronisation of synaptic inputs is responsible for enhancing the 
effectiveness of synapses by increasing strength of transmission. Many others have found 
general abnormal synchronisation in the gamma band (Uhlhaas & Singer, 2010) as well as 
changes in gamma power in both human schizophrenic patients and animal models (Hong et 
al, 2009). The majority of studies on gamma and schizophrenia have focussed on the lower 
gamma range (around 30-80 Hz), but there is also increasing evidence for impairment in higher 
frequency gamma oscillations (Grutzner et al, 2013). Abnormal gamma activity has been 
shown to occur not only in response to sensory stimuli and during cognitive task completion 
but also during a resting state in schizophrenic patients. Experiments conducted on twins have 
shown that these resting state changes are highly heritable and that changes persist despite 
the use of anti-schizophrenia drug treatment in patients (Uhlhaas & Singer, 2010). Thus, 
supporting a causal role of abnormal oscillatory activity in core schizophrenia development 
and pathology.  
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1iv | Aims and rationale 
 This study aimed to characterise changes across an extended gamma frequency range 
(30-120 Hz) in line with more recent research in the literature. The design of this study can be 
separated into three experimental approaches, all principally aiming to characterise changes 
in gamma activity in rat models of schizophrenia. In all experiments, local oscillatory activity 
was recorded in the visual cortex (VC), hippocampus (Hip) and prefrontal cortex (PFC). These 
areas were originally chosen due to their crucial involvement in completion of a visual paired 
associative learning task (sPAL), used for behavioural experiments.  
There are a variety of in vivo techniques for measuring neural oscillations that have 
been extensively studied in both humans and model species. In rats, intracranial EEG recording 
is achieved via insertion of electrodes into the brain and recording directly from the area of 
interest. The voltage difference between this recording site and a reference electrode placed 
elsewhere in the brain is amplified to give a signal for neural network activity in the area of 
interest (del Campo et al, 2009). Intracranial measurement of EEG activity is considered to be 
more accurate than placement of electrodes on the skull as there is less signal loss and noise 
created via tissue conduction (Valiante & Carlen, 2014), making intracranial recording the 
method of choice for this study. The first set of experiments conducted combined intracranial 
electroencephalographic (EEG) recording with behavioural testing in freely moving animals 
following systemic PCP injection, to test the hypothesis that systemic PCP treatment increases 
gamma power during completion of a cognitive task but decreases gamma synchronisation. 
The second set of experiments involved intracranial EEG recording after systemic 
treatment with an NMDAR antagonist again, but this time ketamine was used instead of PCP 
and experiments were conducted on terminally anaesthetised rats. Ketamine has a slightly 
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lower affinity for the NMDAR than PCP but is still a widely accepted antagonist when used to 
recreate NMDAR hypofunction (Frohlich & Van Horn, 2013); ketamine is also known to ‘wash 
out’ more quickly than PCP, making it an attractive choice for these terminal experiments. The 
hypothesis here was that systemic ketamine treatment causes an increase in gamma power 
yet also causes desynchronisation between areas in the brain – affecting inter-area 
communication, which could be the cause of poor cognitive task performance seen in 
schizophrenia. Using anaesthetised rats for this experiment eliminated electrical activity 
generated by muscle movement in freely moving animals from the recording situation, so only 
true EEG activity in recording areas should have been present after artefact removal.  
The final set of experiments aimed to further characterise the specific effect of 
ketamine on gamma activity in local neural networks. This was achieved by local injection of 
ketamine to the same areas of interest in the brain as previous whilst conducting intracranial 
EEG recording. It is thought that systemic treatment with ketamine changes gamma activity 
in a neural region by causing NMDAR hypofunction in local neural networks. These 
experiments were designed to directly test this theory in an attempt to elucidate where 
ketamine is actually acting in the brain and the implications of this in schizophrenia.  
Using these three experimental approaches allowed comparisons to be made between 
neural oscillatory activity in freely moving and anaesthetised rats and between ketamine and 
PCP as NMDAR antagonists, helping to further validate the use of these drugs in modelling 
schizophrenia. This combinational approach is necessary for the translation of basic 
neuroscience to cognitive and behavioural symptoms known to occur in schizophrenia.  
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- METHODS - 
 
Animal husbandry and ethical statement 
Adult male Lister Hooded rats (Charles-River, Margate, UK) were used for all experiments and 
housed in groups of 3-4 under a 12 hour light/dark cycle. All procedures carried out complied 
with University of Birmingham internal regulations and those set out by the Home Office and 
European legislation under the Animals (Scientific Procedures) Act 2013. 
 
2i | Freely moving rat experiments 
Completion of sPAL task under control and PCP conditions 
Six rats were previously trained by undergraduate students (H. Fowler & W. Clarke) to 
complete an sPAL task in an automated Bussey-Saksida rat touch screen chamber (Campden 
Instruments Ltd, Loughborough, UK). This task was chosen as schizophrenia patients have 
been shown to have decreased ability to complete similar tasks. The task consisted of two 
identical pictures appearing on an infra-red touch screen in two different locations, one in the 
correct location learnt by the rat and the other in an incorrect location (figure 2.1). This test 
assesses the rat’s ability to associate both an object and location, which requires integrative 
use of the PFC, Hip and VC - hence why it was chosen for this study.  
The rat was rewarded with a 45 mg sucrose pellet (Sandown Scientific, Hampton, UK) 
for each correct touch and ‘punished’ for wrong touches by the chamber light switching on 
for 5 seconds – extending the intertribal interval, and an ‘incorrect tone’ sounding. The task 
was executed and analysed using ABET II touch software (Lafayette Instrument, Lafayette, 
USA) and the touch screen was controlled by Whisker software (Cambridge University, UK). 
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Rats were kept at approximately 90% of their individual estimated ad libitum weight by 
rationing standard rat ‘chow’ in order to ensure motivation for task completion (Ward et al, 
2013), water was provided ad libitum. 
Figure 2.1| Images and layout used on the touchscreen for sPAL testing of rats in behavioural 
testing chamber. The correct locations shown are the ones learnt by rats; during task completion 
two of the same image were shown to the rat – one in the correct position, the other in an 
incorrect position.  
 
Recording of neural oscillations during task completion  
After rats were deemed proficient in task completion, electrodes were implanted and 
secured in the skull (surgery completed by M. Vreugdenhil). Implanted electrodes were made 
using 50 µm Formvar insulated 80% Nickel 20% Chromium wire (Advent Research Materials, 
Oxford, UK). Two wires were twisted and then cut to give a longer and shorter length to 
facilitate two separate recording channels of data in the area of implantation (figure 2.2), 
giving six overall recording channels.  
Having two different recording sites in the same area of implantation can be used to 
calculate local activity via subtraction of the two recording channels or counteract poor 
recording in one channel - as there are two channels to obtain data from. For Hip and VC 
electrodes, the difference between the two lengths was 0.5 mm. For the PFC the electrode 
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length distance was 1 mm to facilitate recording from the same layer in the prelimbic cortex 
(PrL; longest electrode) and cingulate cortex (Cg1; shorter electrode). 
Figure 2.2| Electrodes were constructed to facilitate recording from two different areas. Image 
shows a typical set of twisted NiCr wire electrodes used for recording from the PFC, VC and Hip. 
Distance between lengths for VC and Hip – 0.5 mm, distance between lengths for PFC – 1 mm 
(allowing recording in PrL and Cg1 areas). 
 
The axis of co-ordinates for surgery are typically abbreviated as listed; AP: anterior-
posterior, ML: medial-lateral and DVC: dorsal-ventral. Electrode placements for connection to 
headstage were as follows (from Bregma); PFC: AP 2.5, ML 1.3, DVC -3.7; Hip: AP -4.0, ML 2.0, 
DVC -2.2; VC: AP -6.0, ML 2.5, DVC -1.2. Angles for insertion of recording electrodes were as 
follows: PFC 10°, VC/Hip 0°. The headset was anchored to the skull with four screws positioned 
at AP -1.5, ML 3; AP -1.5, ML -3; AP -10.5, ML 1.5; AP -10.5, ML -1.5. The two screws positioned 
at the back of the skull were used for reference and grounding (figure 2.3). 
An 8-channel pre amplifier headstage (MP8A Multichannel systems, UK) was used to 
amplify voltage difference with the reference electrode. The headstage was attached to a 
tether mounted on a slip-ring commutator, which allowed the rat to move around the 
chamber unhindered. Further amplification - giving 50x total, and filtering was carried out by 
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AM systems 3600 16-channel amplifier and band-pass filtered at 0.5-500 Hz. The signal was 
digitised and sampled at 2 kHz using a CED power 1401 interface (Cambridge Electronic 
Design, Cambridge, UK).  
Figure 2.3| Recording electrodes were implanted in VC, Hip and PFC to record local EEG activity. 
Schematic diagram of rat skull showing electrode and anchor screw placements in freely moving 
rats. Coloured circles indicate the locations of recording electrodes: PFC (blue) – prefrontal cortex, 
Hip (green) – hippocampus, VC (red) – visual cortex. White circles indicate anchor screws with R 
being the reference screw and G being the grounding screw. 
 
All rats completed the sPAL task under control tethered conditions and whilst under 
the influence of PCP. Rats were injected subcutaneously with 1 mg/ml PCP in physiological 
saline to give 1 mg/kg systemic dose or with 1 ml/kg saline only (vehicle) immediately prior to 
being connected to a tether for recording and placed in the testing chamber to start the task. 
For PCP trials the task ran for 180 minutes and for controls 90 minutes; recording of neural 
oscillations was carried out throughout the duration of all trials.  
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Data analysis of freely moving rat experiments 
 Neural oscillations were recorded from PrL, Cg1, Hip and VC using Spike software 
(Spike2 v7.08, Cambridge Electronic Design, UK) to give six original channels of raw data. Spike 
was then used for initial analysis and preparation of channel data. Traces were first ‘cleaned’ 
before data could be extracted from recordings for further analysis. In certain rats where 
recording of a particular channel had failed, this channel was disregarded. This was also the 
case for when certain channels could not be deemed consistently reliable throughout the 
length of recording.  
EMG activity (generated by muscle movement) and any recording artefacts were 
removed via a software script in Spike (ArtRem) and by manual deletion. Fast Fourier 
transforms (FFTs) were used to produce power spectra; FFT size 2048 and Hanning window 
applied. Power spectra were taken from 100 s sections for remaining channels covering the 
entire length of recording from a control and PCP file for each rat. Spectral power was assessed 
in known physiological ranges for neural oscillations, namely: theta (3-8 Hz), alpha (8-13 Hz), 
beta (13-30 Hz), gamma (30-120 Hz) and fast (120-250 Hz). Average values for power during 
the 100 s sections were calculated for each data channel during control and PCP trials. From 
average power in the gamma range, the time of maximum PCP effect for each rat was 
determined and a 500 s epoch of this used for comparisons with control.  
PrL, Cg1 and the most effected VC and Hip channels (where available in individual rats) 
were FIR (finite impulse response) band pass filtered to give low frequency gamma oscillations 
(LFG; 30-80 Hz) and low pass filtered to give ‘slow’ (<10 Hz) oscillations containing theta 
activity. From this, cross-correlograms were generated for the same 500 s period used for 
power analysis (time at which PCP had maximal effect) and the corresponding control period. 
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Frequencies compared were: slow, LFG and low frequency gamma power (LFGP). Gamma 
power was calculated by applying root mean squared amplitude process to original traces 
using a time constant of 0.02.  
 
2ii | Anaesthetised rat experiments 
Surgery and preparation for EEG recording under terminal anaesthesia 
 Twelve rats (230-355g) were used for experiments under terminal anaesthesia. Rats 
were initially anaesthetised in an induction chamber with 5% isoflurane in oxygen before 
receiving an intraperitoneal injection of 0.7 mg/kg urethane. Rats were then placed under 2% 
isoflurane in oxygen for 30 minutes before receiving a second intraperitoneal injection of 0.7 
mg/kg urethane. A 0.01 mg/kg medetomidine bolus injection was administered 20 minutes 
after the second urethane injection, before attaching a subcutaneous drip filled with 0.005 
mg/kg medetomidine in sterile saline. The drip was attached to a syringe driver (Graseby 
Medical Ltd, Watford, UK) with the speed of the driver set to deliver 0.03 mg/kg/h. The rat’s 
head was then shaved and cleaned in preparation for surgery. Once no pedal reflex remained 
the rat skull was fixed into a stereotactic frame via ear bars; 5% EMLA cream (AstraZeneca, 
UK) was applied inside the ears before securing the bars to minimise discomfort. An incision 
was made along the middle of the skull and the skin held apart with wound clips for the 
remainder of the procedure. Membrane layers covering the skull were scraped away and any 
bleeding stopped before the skull was cleaned with 3% hydrogen peroxide solution and sterile 
saline. A thin layer of light cured resin (Ultradent Products Inc, Utah, USA) was applied to the 
surface of the skull in preparation for drilling of insertion holes. All insertion holes were then 
drilled in the skull using a 0.8 mm diameter drill bit and the dura surrounding the brain 
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underneath opened, this concluded surgery. After completion of surgery, the medetomidine 
drip speed was titrated to suit individual rats’ anaesthetic depths (usually around 0 - 0.01 
mg/kg/h). Depth of anaesthesia throughout surgery and experimental procedures was 
monitored by regular pedal withdrawal checks and taking readings for breathing rate at 
regular intervals. Temperature of the rat was controlled throughout surgery and experimental 
procedures by an automatically adjusted heating pad with core temperature being recorded 
via a rectal probe (ATC1000, World Precision Instruments).  
Holes were drilled for insertion of recording electrodes in VC, Hip and PFC at the same 
co-ordinates used in freely moving rat experiments.  A hole was then drilled at AP -7.8, ML 1.8 
(relative to Bregma) for insertion of a stimulating electrode into the pontis oralis (PO). Holes 
were also drilled for insertion of guide cannulas in VC, Hip and PFC to be used for local 
applications of ketamine in these areas. The co-ordinates for these guide cannula holes (from 
Bregma) were as follows: PFC: AP 2.0, ML 0.8, DVC -1; Hip: AP -3.5, ML 1.5, DVC -1; VC: AP -
6.0, ML 1.7, DVC 0. When insertion cannulas (34G silica pipette filling fibre; WPI, Sarasota, 
USA) were placed into guide cannulas for local injection, the actual DVC value for each area 
was deeper due to the cannula having an insertion stop that ensured a fixed distance of 
extension from the end of the guide cannula. Final DVC values were as follows: PFC: 3, Hip: 
2.5, VC: 1. Angles for insertion of guide cannulas were as follows: PFC 0°, VC/Hip 10°. Guide 
cannulas were made from 28 gauge stainless steel. The method used for construction of 
electrodes was identical to as described previously. Recording electrodes were inserted to the 
same depths as stated previously and guide cannulas inserted alongside before both were 
secured with light cured adhesive resin. Recording electrodes were connected to a headset as 
described previously using gold connector pins and a connected grounding wire placed under 
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the skin of the rat. The reference screw used for terminal experiments was the same as that 
used in freely moving experiments described previously but was this time placed at AP -10, 
ML -2.5 relative to Bregma (figure 2.4). The headset was connected to the same preamplifier 
headstage as stated previously. The stimulating electrode was inserted into PO at DVC values 
between 5 and 6 mm at an angle of 0°.  
Figure 2.4| Guide cannulas were implanted proximally to recording electrodes. Schematic 
diagram of rat skull showing electrode and cannula placement sites for terminal experiments. 
Closed coloured circles indicate the locations of recording electrodes, open coloured circles 
indicate the locations of guide cannulas: PFC (blue), Hip (green), VC (red). Location of stimulus 
electrode in PO is indicated by the open black circle. White circle containing R denotes the 
reference screw. 
 
Amplification and recording procedures were the same as described previously for recording 
of neural oscillations during sPAL task completion in freely moving rats. Efforts were made to 
conserve implantation techniques across terminal and freely moving in vivo protocols in order 
to minimise recording differences and allow comparisons of data to be more valid.  
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Determining stimulation level to achieve cortical activation 
 Rats under terminal anaesthesia do not display neural activity comparable to those 
recorded in freely moving awake animals. The trace is typically dominated by slow ‘sleep like’ 
waveforms and can vary dramatically throughout the experimental time. To study changes in 
neural oscillations induced by drug treatments it is also desirable to have an ‘activated’ cortex, 
as this is the closest mimic of an awake animal.  It was decided that electrical stimulation of 
brainstem nuclei would be used to achieve this stable activated state. A pilot experiment using 
one male Lister Hooded rat was undertaken to determine the most effective place for 
stimulation. It was found that stimulation of PO resulted in the longest level of activation (see 
results, figure 3.6), making it the chosen stimulation site for terminal experiments. 
 Once all electrodes were connected and neural activity was being recorded in every 
channel, electrical stimulations were started to determine the most effective stimulus 
electrode depth. The stimulus electrode was initially placed at DVC 5.0 and a 0.5 mA-1.0 mA 
stimulus applied at depths in steps of 0.25 mm down to DVC 6.0. The stimulus electrode was 
fixed at the depth at which the most effective level of cortical activation was achieved. 
Electrical stimulation was delivered via a constant current isolated stimulator (Digitimer Ltd, 
Welwyn Garden City, UK). A 100 Hz 50 pulse stimulus train at the lowest sufficient amperage 
for cortical activation was given every 60 s throughout experimentation.  
 
Administration of ketamine under terminal anaesthesia  
Ketamine, dissolved in sterile saline, was administered subcutaneously during nine of 
the terminal experiments; three rats received a dose of 10 mg/kg, six rats received 4 mg/kg. 
Sufficient washout time to re-establish a reliable baseline was allowed after systemic 
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ketamine treatment in rats where both systemic and local protocols were used, systemic 
ketamine was given either before or after local injections.  
Ketamine was infused locally into VC, Hip and PFC in all rats with time being allowed 
for washout after this also. 5 µg/µl ketamine dissolved in artificial cerebral spinal fluid (aCSF) 
was used for local injection. Vehicle injections using aCSF have been performed previously in 
the lab and caused no change to oscillatory activity in the brain. Either an infusion pump (KDS 
311CE, kd Scientific, RoYem Scientific Limited, UK) containing a Hamilton Syringe or a ‘micro-
pump’ developed by researchers at Boise State University (S. Barker, Idaho, USA) was used to 
deliver local injections. Both were calibrated to deliver 1 µl of ketamine at a rate of 0.333 
µl/min. Pumps were connected to an insertion cannula made of 150 micron silicon hollow 
fibre which fitted inside of implanted guide cannulas as described previously (figure 2.5).  
 
 
 
 
 
 
 
 
 
 
Figure 2.5| Insertion cannulas were implanted proximally to recording electrodes in the area of 
interest.  Image shows part of rat skull containing Hip electrode and guide cannula to illustrate 
arrangement. ‘Cannula’ denotes metal guide cannula, ‘Insertion’ denotes silicon insertion cannula 
used for local injection of ketamine. The recording electrode is located to the right of the cannula 
in this image.  
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After placement of the insertion cannula into tissue, sufficient time (5-10 minutes) was 
allowed to re-establish a stable baseline before injections were started. The insertion cannula 
was left in place at least 10 minutes after the injection had finished to prevent any backflow 
of solution. 
 
Data analysis of terminal experiments 
Spike software was used for collection of raw data and cleaning of traces. Stimulation 
artefacts were removed using an artefact removal script and any obvious background 
artefacts removed manually.  Virtual channels were created for VC and Hip by subtraction of 
the two recording channels in these areas. This removed shared line noise and shared non-
local activity that may have been recorded through volume conduction. These virtual channels 
were then used in analysis of VC and Hip activity; for PrL and Cg1, original recording channels 
were used.  
FFTs were used to produce power spectra, with FFT size 2048 and Hanning window 
applied. For local ketamine injections, power spectra were taken from 60 s sections before 
and after injection with ketamine. Average power during the 60 s sections was calculated for 
PrL, Cg1, VC and Hip during baseline recording and after injection. For systemic ketamine 
experiments, power spectra were generated from 100 s sections before and after injection – 
as was used for systemic PCP analysis. From the average time course for gamma power, the 
time of maximum ketamine effect was determined for each recording location by averaging 
the three data points encompassing the value furthest away from baseline readings. This 
corresponded to a 180 s epoch for local injections and a 300 s epoch for systemic injections, 
baseline values were taken for the same length of time prior to injection start.  
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Band pass filtering was applied to PrL, Cg1, VC and Hip channels to give LFG, and High 
Frequency Gamma (HFG; 80-120 Hz) oscillations; low pass filtering was applied to give ‘slow’. 
LFGP and HFGP were generated by applying a root mean squared process to LFG and HFG 
traces respectively. From this, cross-correlograms were generated for the same epoch used 
for power analysis (time at which ketamine had maximal effect) and the equivalent baseline 
period before injection. Numerical values of these correlation waveforms were extracted into 
a spreadsheet for further analysis.  
 
Statistics  
 Shapiro-Wilks test for normality was used on all data sets. Comparisons were made 
between control/baseline recordings and recordings conducted following drug treatments. 
Where Shapiro-Wilks was found to be significant, related samples Wilcoxon signed rank test 
was used. Related samples paired T-tests were used when data was normally distributed.   
 
Injection of dye and TTX to validate local injection protocol 
 Injections were delivered as described previously for local injection of ketamine into 
VC, Hip and PFC. In one rat, 1 µl of blue dye was injected at a rate of 0.333 µl/min in each 
injection site sequentially. The brain was then dissected out, following cervical dislocation of 
the rat, and sliced to examine dye location. In five rats 1 µl of 10 ng/ml Tetrodotoxin (TTX) was 
injected at a rate of 0.333 µl/min into each injection site sequentially, whilst recording EEG 
activity. Both of these protocols were undertaken at the end of experiments, as electrical 
activity in the brain would not have recovered to a baseline situation. 
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Pilot experiment: local ketamine injection into Nucleus Basalis 
 In two rats, ketamine was injected locally into the Nucleus Basalis (NB) using the same 
protocol as described previously for local ketamine injection. This was an additional 
experiment conducted at the end of this study to form the basis of a future set of experiments. 
EEG was recorded and PO stimulation used as described previously also. The co-ordinates for 
insertion of NB cannula (from Bregma) were: AP -1.8, ML 3.0, DVC -7.8.  
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- RESULTS - 
3i | PCP experiments in freely moving rats 
PCP caused behavioural changes during sPAL task completion  
The six rats used for the series of PCP experiments had been previously trained and 
were competent in completion of the sPAL task. Therefore, all rats were comfortable being 
handled and whilst in the testing chamber – importantly this meant no signs of stress were 
observed that may have caused changes in neural activity not related to PCP kinetics. During 
control trials, where the rat was injected with a vehicle immediately before being placed in 
the chamber, task completion was to the standard level of proficiency acquired during training 
and no abnormal behaviour was observed. Treatment with 1 mg/kg PCP caused profound 
changes in behaviour whilst rats attempted to complete the task, with the main affect being 
hyperactivity followed by moderate ataxia. The ability to complete the task was affected; rats 
regularly initiated the task, failed to select an image, yet attempted to collect a sugar pellet. 
Behavioural changes were observed as quickly as 10 minutes post injection and were evident 
in all rats until around 60 minutes, by which time movement had returned to near normal. By 
90 minutes most rats had lost interest in task completion and mainly spent the remaining time 
resting, indicating that any major behavioural effects of PCP had worn off by this time point.  
As well as induced behavioural changes by PCP treatment, changes were observed in 
task proficiency. The average percentage ‘correct touches’ value for control trials was 86.5%, 
as there was a 50% chance of making a correct touch (due to two images being displayed) this 
can be viewed as 36.5% above being correct by chance. This was significantly decreased by 
23.9% during PCP trials [n=6, p=0.028], making percentage correct performance only 12.6% 
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greater than chance whilst under the influence of PCP.  This illustrates that 1 mg/kg PCP is 
sufficient to decrease paired associative learning performance. Correction trials were offered 
to the rat after an incorrect touch was made in the task, rats usually remember their previous 
wrong choice and so choose the correct image in a correction trial. Correction trial number 
significantly increased by an average of 57.5% in PCP trials compared to controls [n=6, 
p=0.027]. This indicates that rats persistently chose the wrong image in the task when 
previously they were able to remember which image should be the correct one knowing they 
were initially incorrect. This result is consistent with impairments in working memory which, 
as stated earlier, is a key symptom of schizophrenia.  
 
From raw traces to EEG data 
 Traces from recording channels contained many artefacts (figure 3.1a) and so needed 
to be ‘cleaned’ before any further power analysis could be completed (figure 3.1b). Clear EMG 
activity and recording artefacts are visible in the raw trace, which were manually removed. It 
was from these cleaned traces that power spectra were then generated for analysis (figure 
3.2). Spectra were generated for PCP and control files from ‘cleaned’ traces for each recording 
area. The numerical values for these power spectra were separated into physiological ranges, 
e.g. 30-80 Hz for LFG, and used for statistical comparisons. 
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Figure 3.1| Traces had to be cleaned and movement artefacts removed to leave EEG activity. (a) 
shows 3 seconds of recording from PrL for a rat completing sPAL after injection with PCP, EMG 
activity from chewing is apparent at the start of the trace and a large wave recording artefact; (b) 
shows 3 seconds trace from the same channel after artefact removal, revealing gamma and theta 
activity. Note the scale difference between a and b. 
Figure 3.2| An example of the power spectra generated for analysis of changes to power 
following PCP treatment. Shown is a power spectrum generated from the trace in figure 1b, which 
was recorded in PrL during completion of sPAL after PCP injection. Data is shown on a log power 
scale for recorded activity in 0-250 Hz frequency range. 
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PCP caused increased gamma power in all recording areas 
 The time of maximal PCP effect occurred firstly in Hip and VC, at around 800s post 
injection time. Then followed the PrL and Cg1, with their peaks occurring at around 1000s 
(figure 3.3). Gamma power remained slightly elevated above baseline levels in all areas after 
120 minutes – up until the end of recording. At the 60 minute mark, the time at which 
behaviour appeared to have returned to normal in all rats, gamma power was still around 50% 
higher than control values in VC, Hip and Cg1. This indicates that changes to EEG activity 
caused by PCP are much longer lasting than effects on behavioural measures. 
Figure 3.3| Systemic PCP injection caused an increase in gamma power in all recording areas 
throughout sPAL task completion. Graph shows mean changes in gamma band power in all 
recording areas throughout EEG recording during PCP trials in all rats [n=6]. Line colours: purple – 
Cg1, green – Hip, red – VC, blue – PrL. Gamma power was normalised to control recordings for 
each rat.  
 
Total gamma power (sum of power in 30-120 Hz range) at the peak of PCP effect was 
significantly higher than during control trials for all rats. PCP power values were normalised to 
0 1 0 0 0 2 0 0 0 3 0 0 0 4 0 0 0 5 0 0 0 6 0 0 0 7 0 0 0
0 .0
0 .5
1 .0
1 .5
2 .0
2 .5
T im e  [s ]
N
o
r
m
a
li
s
e
d
 p
o
w
e
r
Chapter 3 | RESULTS | A G Wilcox 
 
 
[25] 
 
a baseline by dividing values by their control counterpart at the same time point. Normalising 
allowed data from each recording area to be more easily comparable and accounted for 
natural changes occurring in EEG over the length of task completion. Following PCP injection: 
gamma power in PrL was increased by 49% [t(4)=3.930, p=0.017], VC increased by 86% 
[t(4)=5.938, p=0.004] and Hip increased by 98% [t(4)=5.028, p=0.007]. The largest change 
caused by PCP in all areas of interest was recorded in Cg1, which increased by 115% 
[t(4)=10.877, p<0.001]. 
 
Recorded traces were filtered before completion of cross correlation analysis  
Simultaneous recording of different neural regions allows changes in synchronicity 
between areas to be studied. In order to complete cross-correlation analysis, traces were 
initially filtered to leave oscillations in relevant ranges. These were LFG, fluctuations in LFGP 
and slow (<10 Hz). FIR digital filtering was used to achieve this (figure 3.4). Cross-correlograms 
were then generated from these filtered traces of different frequencies, comparing the phase 
relationships between activity in recording areas. An example is shown comparing the 
relationship between LFG in Hip (used as reference) and LFG in PrL (figure 3.5). For the 
example shown, the correlation peak is not exactly 0, this indicates that any measured 
correlation is a true relationship and not shared line noise. The peak of correlation is slightly 
negative – indicating that that peak of oscillation in PrL occurs slightly before that in the Hip. 
The max correlation value of a cross-correlogram is a measure of the strength of correlation 
between the two areas compared; a higher value indicates greater phase synchrony. For The 
example correlograms shown, the max correlation of the peak was higher during the control 
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recording [0.17] than during the PCP recording [0.09]. This change was observed frequently 
after PCP treatment and will be discussed in more depth with other changes in the next 
section.  
Figure 3.4| Raw traces were filtered to leave activity in the relevant frequency bands needed 
for cross correlation analysis. Example filtered traces taken from 1 s of PrL recording; a – raw 
clean trace containing all recorded frequencies; b – slow oscillations, low pass filtered <10 Hz; c – 
LFG oscillations, band pass filtered 30-80 Hz; d – LFGP, root mean square amplitude process 
applied to trace in c.  
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Figure 3.5| From filtered traces in relevant frequency bands, cross-correlograms were generated 
showing the phase relationship between recording areas. Shown are typical cross-correlograms 
taken from LFG recorded simultaneously in Hip and PrL, here Hip was taken as the reference and 
the phase of PrL compared with it. Control refers to a control trial recording where the rat 
completed the sPAL task without intervention, PCP refers to a recording in which the rat received 
an injection of 1 mg/kg PCP prior to starting the sPAL task. In this example, correlation between 
the two areas decreased following PCP treatment – as indicated by the decreased amplitude of 
the correlogram for PCP. 
 
PCP treatment caused changes to correlations between recorded areas 
 Cross correlation analysis can be used to determine how synchronised activities in 
areas of the brain are with each other, this reflects the phase relationship between oscillations 
generated in each area. Phase synchronicity can be interpreted to reveal changes in the ability 
of the areas analysed to communicate effectively, as synchronisation is required for the 
transmission of information in the cortex (Vinck et al, 2013).  Lower frequency oscillations 
such as theta are also thought to modulate gamma power, thus facilitating synchronisation 
and communication (Doesburg et al, 2012). Therefore, disruption to these relationships 
induced by drug treatment can be viewed as detrimental to communication in the cortex.  
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When cross-correlations of LFG between all recorded areas were analysed, all areas 
showed a PCP induced decrease in the max correlation value (table 3.1). Generally, the 
greatest decreases occurred between the areas located furthest apart (e.g. Hip and PrL/Cg1) 
and the smallest decreases between areas located close together in the brain (e.g. PrL and 
Cg1). As six comparisons were made of LFG correlation between recorded areas, it was 
decided that a Bonferroni correction would be appropriate – giving a new alpha value of 0.008. 
The decrease in max correlation between Hip and Cg1 was the only change still deemed 
statistically significant under the new corrected significance level (see table 3.1). 
Correlations Max correlation Significance 
Areas compared Control (sem) PCP (sem) t value p value df 
Hip-PrL 0.157 (0.018) 0.107 (0.015) -3.349 0.029 4 
Hip-Cg1 0.164 (0.009) 0.091 (0.005) -5.036 0.007 4 
Hip-VC 0.473 (0.132) 0.451 (0.134) 1.235 0.305 3 
PrL-Cg1 0.593 (0.075) 0.590 (0.076) 0.158 0.882 4 
VC-Cg1 0.213 (0.058) 0.160 (0.060) -2.466 0.069 4 
VC-PrL 0.176 (0.065) 0.136 (0.032) -0.852 0.457 3 
Table 3.1| Systemic PCP caused a decrease in inter-area LFG correlation during sPAL task 
completion. Changes in max correlation value between LFG in recorded areas during control and 
PCP treated trials for all available rats. PCP refers to 500 s of data encompassing highest peak in 
gamma power effect determined previously, control refers to the same 500 s time point in a 
control recording. The first channel listed in ‘areas compared’ was used as the reference that the 
second channel listed was compared to this. * denotes significant decrease in max correlation 
value when α = 0.05; * denotes significant when α = 0.008. Data is shown as the mean value with 
the sem (standard error mean) for these values in brackets. 
 
The same trend of decrease for LFGP inter-area correlation occurred as for LFG; max 
correlation decreased and the largest decreases were observed between those areas furthest 
apart spatially. Two significant changes were revealed during analysis of LFGP-LFGP 
relationships (table 3.2), these were between Hip-PrL and Hip-Cg1 – the same two correlations 
* 
* 
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that were also initially significant when comparing LFG. As the same number of statistical 
comparisons were made as previous, the adjusted alpha value after correction was 0.008. 
Again, the decrease in max correlation between Hip-Cg1 was the relationship deemed still 
significant after correction.  
Correlations Max correlation Significance 
Areas compared Control (sem) PCP (sem) t value p value df 
Hip-PrL 0.073 (0.009) 0.039 (0.006) -3.165 0.034 4 
Hip-Cg1 0.058 (0.009) 0.047 (0.006) -6.365 0.003 4 
Hip-VC 0.324 (0.106) 0.273 (0.103) 2.497 0.088 3 
PrL-Cg1 0.400 (0.061) 0.394 (0.078) 0.198 0.852 4 
VC-Cg1 0.070 (0.017) 0.038 (0.009) 2.492 0.067 4 
VC-PrL 0.111 (0.020) 0.071 (0.020) 1.834 0.164 3 
Table 3.2| Systemic PCP caused a decrease in inter-area LFGP correlation during sPAL task 
completion. Changes in max correlation value between LFGP in recorded areas during control and 
PCP treated trials for all available rats. PCP refers to 500 s of data encompassing highest peak in 
gamma power effect determined previously, control refers to the same 500 s time point in a 
control recording. The first channel listed in ‘areas compared’ was used as the reference that the 
second channel listed was compared to this. * denotes significant decrease in max correlation 
value when α = 0.05; * denotes significant when α = 0.008. Data is shown as the mean value with 
the sem (standard error mean) for these values in brackets. 
 
As stated earlier, Cg1 showed the greatest increase in gamma power after injection 
with PCP. The fact that the most significant decrease in correlation value occurred in 
correlations containing Cg1 indicates that although gamma power is increased by PCP, the 
synchronisation of Cg1’s gamma power with other areas – such as Hip, is decreased. As 
explained earlier, this may indicate disruption in communication between these areas. Also, 
when looking at LFG and LFGP the two significant changes found in both occurred when 
comparing prefrontal areas to Hip. This may have contributed to the decreased performance 
in sPAL as both of these areas are key for task completion. No clear change in phase 
* 
* 
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relationship was observed for slow wave to LFGP oscillations (table 3.3), indicating that the 
modulation of gamma power by slower frequencies was unaffected by PCP treatment. 
Correlations Max correlation Significance 
Areas compared Control (sem) PCP (sem) p value 
Hip-PrL 0.038 (0.016) 0.040 (0.016) 0.949 
Hip-Cg1 0.023 (0.002) 0.029 (0.005) 0.135 
Hip-VC 0.079 (0.015) 0.058 (0.016) 0.156 
PrL-Cg1 0.018 (0.004) 0.020 (0.005) 0.661 
VC-Cg1 0.028 (0.003) 0.037 (0.009) 0.340 
VC-PrL 0.037 (0.016) 0.038 (0.019) 0.905 
Table 3.3| Systemic PCP caused no significant changes to slow-LFGP inter-area correlation 
during sPAL task completion. Changes in max correlation value for slow-LFGP in recorded areas 
during control and PCP treated trials for all available rats. PCP refers to 500 s of data encompassing 
highest peak in gamma power effect determined previously, control refers to the same 500 s time 
point in a control recording. The first channel listed in ‘areas compared’ was used as the reference 
that the second channel listed was compared to this. Data is shown as the mean value with the 
sem (standard error mean) for these values in brackets.  
 
3ii | Systemic ketamine experiments in anaesthetised rats 
Electrical stimulation was used to create an active cortex recording situation 
 Neural activity recorded from rats under terminal anaesthesia were dominated by slow 
waves and showed a typical fluctuating ‘deep sleep like’ pattern of activity (figure 3.6a). For 
the purpose of this study, an activated cortex was required that was more comparable to that 
of awake rats used for PCP experiments. To achieve this, 0.5 - 1 mA electrical stimulation 
(detailed in methods) via the PO was used. The PO is known to have a role in control of REM 
sleep and electrical PO stimulation has been previously found to generate theta (Brown et al, 
2012). As well as activating the cortex to a state where changes in gamma activity could be 
induced and recorded, stimulation created a reproducible baseline situation comparable 
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among all rats used (figure 3.6b). It was from this initial ‘activated baseline’ state that all 
following terminal ketamine experiments were conducted.  
Figure 3.6| Electrical stimulation via the pontis oralis created an active cortex which could be 
deemed a stable baseline for terminal experiments. Traces show typical effect of electrical 
stimulation via PO on recording areas. a - 7 seconds of trace from Hip before stimulation: slow 
waves dominated recording, b - 7 seconds of trace from same Hip channel following stimulation: 
slow waves were supressed and a stable baseline created, c - 3 seconds trace from PrL following 
stimulation (same time scale used as figure 3.1 in awake rats, for comparison of recording): 
gamma and theta activity created by stimulation mimics an awake rat.  
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Changes to power were different for recording areas 
 The frequency distribution of power spectra generated for each recording area 
differed during stimulated baseline recordings (figure 3.7). These differing baseline power 
levels account for differences in absolute power values following ketamine treatment for each 
recording area and highlight the need for normalisation of data.  As well as increasing power 
across the entire gamma range (30-120 Hz), systemic ketamine treatment increased power in 
lower frequency bands such as theta (3-8 Hz).  For Hip and VC, a subtraction of the two 
recording channels in these areas was used to create a local area activity channel (detailed in 
methods).  
 
Systemic ketamine treatment significantly increased gamma power 
As mentioned previously, for terminal recordings a subtraction channel for VC and Hip 
was created – data from these subtraction channels were used for analysis of these areas for 
the following experiments. Gamma power for terminal experiments denotes the power of 
oscillations across 30-120 Hz frequency range, LFGP and HFGP refer to previously explained 
lower and higher power bands within this range. For systemic ketamine experiments, the 
value for peak ketamine effect on gamma power was determined by averaging 300 s of data 
encompassing the highest power value recorded after injection in each rat and then averaging 
these values for all rats.  
In three rats, 10 mg/kg ketamine was given systemically (subcutaneously) under 
terminal anaesthesia whilst recording EEG. Following systemic injection with ketamine: 
gamma power peaked first in Hip and VC, and was then followed by Cg1 and PrL. Peak effect 
Chapter 3 | RESULTS | A G Wilcox 
 
 
[33] 
 
occurred earlier under 10 mg/kg ketamine than 4 mg/kg and 10 mg/kg also caused a greater 
overall increase in gamma power in all channels. Gamma power remained elevated above 
baseline levels under both doses at the end of recording (figure 3.8). 
Figure 3.7| Power spectra from different areas showed different distributions of power 
frequencies before and after systemic injection with ketamine. Example power spectra for 
baseline and systemic ketamine recordings for all areas of interest, showing power of oscillations 
recorded between 0-120 Hz. Blue - PrL, purple – Cg1, red – VC, green – Hip. Systemic ketamine 
increased power in gamma and lower frequencies in all areas. 
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Figure 3.8| Gamma power was increased by systemic injection with 4 mg/kg and 10 mg/kg 
ketamine. Graphs show mean changes to gamma power in all recording areas after systemic 
ketamine treatment [10 mg/kg: n=3, 4 mg/kg: n=6]. Line colours: purple – Cg1, green – Hip, red – 
VC, blue – PrL. Data is shown for 10 mg/kg encompassing the peak of effect, data is shown for the 
length of recording for 4 mg/kg - both were normalised to baseline recordings for each rat before 
averaging.  
 
Data was normalised to the arithmetic mean of values for 300 s - deemed a stable 
baseline, before injection start point. The peak of ketamine effect was taken as an average of 
300 s of data encompassing the highest power value recorded after injection. Following 
systemic treatment with 4 mg/kg ketamine: peak gamma power in Cg1 increased by 50% 
[t(5)=4.568, p=0.006], PrL was increased by 41% [t(5)=3.367, p=0.020] and VC increased by 
31% [t(5)=3.349, p=0.020]. The only increase deemed not significant following 4 mg/kg 
ketamine injection was in Hip, which increased by 35% [t(5)=2.407, p=0.061]. 
Following systemic treatment with 10 mg/kg ketamine: peak gamma power in Cg1 
increased by 150% [t(2)=4.610, p=0.044], PrL was increased by 153% [t(2)=4.760, p=0.041], 
Hip increased by 127% [t(2)=6.096, p=0.026] and VC increased by 114% [t(2)=12.704, 
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p=0.006]. These increases in gamma power were all deemed significant when α=0.05, but as 
the n number for these data was just 3 (compared to n=6 for 4 mg/kg), significant values 
should not be deemed as robust as those for 4 mg/kg.  
 
Additional filtering was needed to obtain high frequency gamma oscillations 
 High frequency gamma oscillations (HFG, 80-120 Hz) and HFGP (root mean squared 
applied to HFG) were used in cross correlation analysis of terminal ketamine data – in addition 
to LFG, LFGP and slow activity described previously in PCP experiments (figure 3.9). 
Figure 3.9| Band pass filtering was used to give HFG and HFGP for cross-correlation analysis of 
terminal experiments. Example filtered traces for cross-correlation analysis: a - 1 second of raw 
Hip recording; b - HFG taken from same trace as in a, band pass filtered 80-120 Hz; c - HFGP, 
amplitude root mean squared applied to HFG trace. 
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Systemic ketamine treatment caused changes to inter-area correlations 
 For cross correlation analysis, data from 4 mg/kg dose experiments were used due to 
higher n number [n=6] and thus greater reliability. An average value was taken for maximum 
correlation during baseline and peak ketamine effect for all rats. The max correlation value for 
HFG between areas was decreased for all correlations after systemic ketamine treatment 
except for between VC-Hip, where correlation slightly increased. This was also the case for 
LFG inter-area correlations, although the decreases were more modest (table 3.4). In both 
cases, the greatest effect on inter-area synchronisation occurred between areas located 
furthest apart. As described previously, a Bonferroni adjusted α value was applied to any 
changes found to be significant when α=0.05. There were no significant changes remaining 
when the adjusted α was applied. 
Correlations Max correlation Significance 
Areas compared Frequencies  Baseline (sem) Ketamine (sem) p value 
Cg1-Hip LFG-LFG 0.301 (0.068) 0.260 (0.051) 0.209 
Cg1-VC LFG-LFG 0.370 (0.125) 0.328 (0.126) 0.120 
PrL-Cg1 LFG-LFG 0.867 (0.035) 0.857 (0.045) 0.430 
PrL-Hip LFG-LFG 0.285 (0.065) 0.255 (0.043) 0.917 
PrL-VC LFG-LFG 0.370 (0.110) 0.332 (0.109) 0.181 
VC-Hip LFG-LFG 0.436 (0.126) 0.462 (0.103) 0.305 
Cg1-Hip HFG-HFG 0.212 (0.052) 0.143 (0.048) 0.050 
Cg1-VC HFG-HFG 0.309 (0.077) 0.204 (0.084) 0.028 
PrL-Cg1 HFG-HFG 0.701 (0.043) 0.659 (0.063) 0.173 
PrL-Hip HFG-HFG 0.212 (0.046) 0.135 (0.043) 0.051 
PrL-VC HFG-HFG 0.308 (0.072) 0.201 (0.067) 0.046 
VC-Hip HFG-HFG 0.465 (0.068) 0.473 (0.074) 0.520 
Table 3.4| Systemic ketamine induced changes to inter-area LFG and HFG correlations. Mean 
changes in max correlation value for LFG and HFG between areas during baseline and systemic 
ketamine recordings [n=6]. Ketamine refers to 300 s of data encompassing highest peak in gamma 
power effect determined previously, baseline refers to 300 s baseline recording before injection. 
The mean value for all rats is shown with the sem for these data in brackets. * denotes significant 
decrease in max correlation value when α=0.05, no changes were significant when α=0.008. 
* 
* 
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 Changes to HFGP correlations between areas followed the opposite trend to those for 
HFG: max correlation value increased between every area analysed. Max correlation value for 
LFGP between all areas of interest also increased under systemic ketamine (table 3.5). This is 
in contrast to systemic PCP injection in freely moving rats, where a decrease in inter-area LFGP 
was observed. However, none of the changes to LFGP or HFGP in these terminal systemic 
ketamine experiments were deemed significant.  
Correlations Max correlation Significance 
Areas compared Frequencies  Baseline (sem) Ketamine (sem) p value 
Cg1-Hip LFGP-LFGP 0.153 (0.056) 0.179 (0.080) 0.463 
Cg1-VC LFGP-LFGP 0.218 (0.147) 0.287 (0.143) 0.345 
PrL-Cg1 LFGP-LFGP 0.787 (0.580) 0.805 (0.068) 0.311 
PrL-Hip LFGP-LFGP 0.138 (0.044) 0.183 (0.069) 0.173 
PrL-VC LFGP-LFGP 0.210 (0.138) 0.284 (0.133) 0.345 
VC-Hip LFGP-LFGP 0.342 (0.105) 0.377 (0.105) 0.174 
Cg1-Hip HFGP-HFGP 0.114 (0.041) 0.154 (0.051) 0.235 
Cg1-VC HFGP-HFGP 0.183 (0.088) 0.211 (0.096) 0.753 
PrL-Cg1 HFGP-HFGP 0.592 (0.060) 0.601 (0.076) 0.722 
PrL-Hip HFGP-HFGP 0.119 (0.033) 0.160 (0.045) 0.304 
PrL-VC HFGP-HFGP 0.184 (0.077) 0.209 (0.085) 0.685 
VC-Hip HFGP-HFGP 0.290 (0.065) 0.380 (0.085) 0.058 
Table 3.5| Systemic ketamine treatment increased inter-area LFGP and HFGP correlation for all 
areas. Mean changes in max correlation value for LFGP and HFGP in areas during baseline and 
systemic ketamine recordings [n=6]. Ketamine refers to 300 s of data encompassing highest peak 
in gamma power effect determined previously, baseline refers to 300 s baseline recording before 
injection. No significant changes were found at α=0.05, sem refers to the standard error mean for 
these data.  
 
Finally, any changes to the modulation of gamma by slow wave oscillations was studied 
using cross correlation analysis. Systemic ketamine caused significant decreases to the max 
correlation value between slow wave activity in both prefrontal areas (PrL and Cg1) and LFGP 
in Hip. Similar to the effect on slow-LFGP following PCP injection in freely moving rats, no real 
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changes to correlation value for slow-HFGP occurred (table 3.6). Correlations between slow 
activity in all areas and LFGP in Hip showed a clear decrease, this indicates that modulation of 
LFGP in Hip by lower frequency oscillations is the most affected relationship following 
systemic ketamine treatment. The modulation of Hip HFGP by slow oscillations was less 
affected by ketamine, and the modulation of HFGP in other areas was even less affected.  
Correlations Max correlation Significance 
Areas compared Frequencies  Baseline (sem) Ketamine (sem) p value 
Cg1-Hip Slow-LFGP 0.124 (0.021) 0.057 (0.011) 0.049 
Cg1-VC Slow-LFGP 0.087 (0.032) 0.090 (0.032) 0.753 
PrL-Cg1 Slow-LFGP 0.087 (0.029) 0.105 (0.029) 0.463 
PrL-Hip Slow-LFGP 0.119 (0.013) 0.050 (0.009) 0.018 
PrL-VC Slow-LFGP 0.088 (0.028) 0.080 (0.028) 0.345 
VC-Hip Slow-LFGP 0.146 (0.026) 0.110 (0.037) 0.276 
Cg1-Hip Slow-HFGP 0.051 (0.011) 0.055 (0.026) 0.917 
Cg1-VC Slow-HFGP 0.064 (0.179) 0.078 (0.021) 0.464 
PrL-Cg1 Slow-HFGP 0.087 (0.206) 0.099 (0.021) 0.187 
PrL-Hip Slow-HFGP 0.059 (0.013) 0.087 (0.305) 0.323 
PrL-VC Slow-HFGP 0.072 (0.016) 0.064 (0.016) 0.684 
VC-Hip Slow-HFGP 0.051 (0.013) 0.048 (0.016) 0.799 
Table 3.6| Systemic ketamine treatment caused significant decreases to slow-LFGP correlations 
between PrL/Cg1 and Hip but caused none for slow-HFGP correlations. Mean changes in max 
correlation value for LFGP and HFGP in areas during baseline and systemic ketamine recordings 
[n=6]. Ketamine refers to 300 s of data encompassing highest peak in gamma power effect 
determined previously, baseline refers to 300 s baseline recording before injection. * denotes 
significant changes at α=0.05, sem refers to the standard error mean for these data, no significant 
results remained so at corrected α=0.008. 
 
3iii | Local ketamine experiments in anaesthetised rats 
Local injection of ketamine caused no significant changes to gamma power 
 1 µl of 5 µg/µl ketamine was injected over 3 minutes into VC, Hip and PFC and changes 
in oscillatory activity measured in VC, Hip, PrL and Cg1 - as previous. Data for all local injections 
* 
* 
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was normalised to an average value for 180 s before injection start point - deemed a stable 
baseline. Peak change in gamma power after injection was taken as 180 s of data 
encompassing the value furthest away from 1 on this normalised baseline. An average effect 
was taken for all individual rat data by calculating the arithmetic mean for all individual rat  
values (table 3.7). 
 
 
 
 
 
 
 
Table 3.7| Local injection of ketamine caused no significant changes to gamma power. Table 
shows percentage change in gamma power (30-120 Hz) following local ketamine injection in 
terminal experiments [PFC injection: n=6; VC/Hip injection: n=5]. Injected refers to the site of 
ketamine injection, recorded refers to the area in which gamma power was taken from following 
this injection. No significant changes were found. 
 
As is shown in table 3.7, no significant changes to gamma power occurred following 
local injection into Hip, PFC and VC. The majority of changes calculated showed no real change 
in power, however some values appear to show a reasonably large effect on gamma power 
despite not being deemed significant. In all of these cases, it is the contribution of mainly one 
data set on the mean change that results in a greater value for percentage change. Although 
Injected Recorded % change p value 
Hip 
Cg1 +23 0.478 
PrL +16 0.500 
VC +8.1 0.103 
Hip +60 0.225 
PFC 
Cg1 +1.3 0.741 
PrL +4.5 0.418 
VC +5.7 0.917 
Hip -7.9 0.069 
VC 
Cg1 +1.1 0.800 
PrL -4.8 0.418 
VC +27 0.136 
Hip +6.3 0.571 
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these data were not deemed outliers, they have altered the peak gamma deviation value that 
is used to calculate percentage change. For example, the greatest effect induced by local 
ketamine treatment occurred in Hip following Hip injection; average gamma power increased 
to a clear peak before returning to baseline. This pattern of change and the level of increase 
was not dissimilar to that observed after 4 mg/kg systemic ketamine injection. However, the 
difference between peak effect and baseline was not deemed statistically significant as in the 
majority of rats a clear peak of change did not occur. Typically following local ketamine 
injection, power fluctuated around baseline values and no clear change was observed (figure 
3.10). Therefore, although percentage change calculated using peak gamma values may 
appear to show substantial increases post injection, the average effect shows no stable overall 
increase in power. These results indicate that local changes in gamma power elicited by 
systemic ketamine treatment are not due to ketamine acting on local networks directly. 
Figure 3.10| Local injection of ketamine into Hip caused percentage increases in recording areas 
when using peak gamma values but none were deemed significant. Average effect on gamma 
power in all recording areas following injection of 1 µl of 5 µg/µl locally into Hip [n=5]. Injection 
start point = 0 s on x-axis, data is normalised to average value for 180 s of baseline before injection 
start. Line colours: Hip – green, VC – red, PrL – blue, Cg1 – purple. 
-360 -180 0 180 360 540 720
1.0
1.2
1.4
1.6
1.8
Time [s]
  
  
  
  
  
  
 N
o
rm
a
li
s
e
d
 p
o
w
e
r
Chapter 3 | RESULTS | A G Wilcox 
 
 
[41] 
 
Local injection of ketamine did not alter inter-area correlation 
Cross-correlation data presented for local ketamine injection focusses on the 
frequencies that were found to be significantly altered by systemic ketamine treatment, 
namely HFG-HFG (table 3.8) and slow-LFGP (table 3.9). Peak effect was taken as the max 
correlation value for 180 s that encompassed the greatest deviation in gamma power from 
baseline values; 180 s of stable data before injection start was taken for baseline.  
Correlations Max correlation Significance 
Local site Areas compared Baseline (sem) Ketamine (sem) p value 
PFC 
Cg1-Hip 0.059 (0.027) 0.063 (0.024) 0.643 
Cg1-VC 0.017 (0.005) 0.017 (0.003) 0.945 
PrL-Cg1 0.698 (0.080) 0.713 (0.074) 0.267 
PrL-Hip 0.057 (0.023) 0.056 (0.022) 0.891 
PrL-VC 0.014 (0.004) 0.017 (0.002) 0.418 
VC-Hip 0.111 (0.058) 0.100 (0.040) 0.917 
Hip 
Cg1-Hip 0.090 (0.042) 0.078 (0.027) 0.483 
Cg1-VC 0.024 (0.006) 0.025 (0.006) 0.837 
PrL-Cg1 0.688 (0.056) 0.729 (0.071) 0.438 
PrL-Hip 0.079 (0.036) 0.079 (0.020) 0.998 
PrL-VC 0.023 (0.006) 0.025 (0.001) 0.679 
VC-Hip 0.048 (0.010) 0.048 (0.007) 0.893 
VC 
Cg1-Hip 0.067 (0.022) 0.059 (0.020) 0.406 
Cg1-VC 0.015 (0.003) 0.030 (0.013) 0.365 
PrL-Cg1 0.759 (0.047) 0.745 (0.054) 0.489 
PrL-Hip 0.062 (0.020) 0.060 (0.021) 0.689 
PrL-VC 0.013 (0.003) 0.020 (0.005) 0.269 
VC-Hip 0.030 (0.001) 0.032 (0.006) 0.760 
Table 3.8| Local injection of ketamine into PFC, Hip and VC did not significantly alter inter-area 
correlation. Table contains mean changes to max correlation value for inter-area HFG during 
baseline and following local injection of ketamine into PFC [n=6], VC and Hip [n=5]. Ketamine 
refers to max correlation value encompassing the greatest deviation in gamma power from 
baseline, baseline refers to max correlation value during baseline recording before injection, sem 
refers to the standard error mean. 
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Correlations Max correlation Significance 
Local site Areas compared Baseline (sem) Ketamine (sem) p value 
PFC 
Cg1-Hip 0.165 (0.038) 0.150 (0.032) 0.459 
Cg1-VC 0.062 (0.020) 0.058 (0.013) 0.787 
PrL-Cg1 0.075 (0.013) 0.071 (0.009) 0.750 
PrL-Hip 0.152 (0.040) 0.014 (0.033) 0.548 
PrL-VC 0.069 (0.021) 0.069 (0.015) 0.753 
VC-Hip 0.113 (0.044) 0.096 (0.039) 0.116 
Hip 
Cg1-Hip 0.157 (0.029) 0.100 (0.027) 0.259 
Cg1-VC 0.029 (0.009) 0.036 (0.005) 0.539 
PrL-Cg1 0.087 (0.024) 0.070 (0.027) 0.263 
PrL-Hip 0.153 (0.027) 0.116 (0.024) 0.162 
PrL-VC 0.028 (0.010) 0.030 (0.004) 0.873 
VC-Hip 0.070 (0.011) 0.065 (0.012) 0.551 
VC 
Cg1-Hip 0.108 (0.021) 0.096 (0.021) 0.568 
Cg1-VC 0.035 (0.001) 0.045 (0.014) 0.606 
PrL-Cg1 0.068 (0.012) 0.073 (0.009) 0.608 
PrL-Hip 0.088 (0.014) 0.098 (0.020) 0.405 
PrL-VC 0.030 (0.013) 0.081 (0.037) 0.164 
VC-Hip 0.074 (0.015) 0.071 (0.021) 0.701 
Table 3.9| Local injection of ketamine into PFC, Hip and VC caused no clear pattern of change to 
slow-LFGP inter-area correlations. Table contains mean changes to max correlation value for 
inter-area slow-LFGP during baseline recording and following local injection of ketamine into PFC 
[n=6], VC and Hip [n=5]. Ketamine refers to max correlation value encompassing the greatest 
deviation in gamma power from baseline, baseline refers to max correlation value during baseline 
recording before injection, sem refers to the standard error mean.  
 
Similarly to changes in gamma power following injection of 5 µg/µl ketamine into the 
PFC, Hip and VC; no significant changes to inter-area correlation occurred for HFG-HFG or 
slow-LFGP. Not only were no changes found significant, but there was no clear pattern of 
change to correlations elicited by local ketamine injection. 
Results for local ketamine injection are clearly in contrast to both systemic ketamine 
treatment under terminal anaesthesia and systemic PCP treatment in freely moving awake 
rats – both of which showed changes in gamma power and correlations. Taken collectively, it 
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can be concluded that local ketamine treatment was unable to recreate the effects on inter-
area synchronisation recorded following systemic treatment. 
 
TTX and dye injection were used to validate local cannula placement 
 At the end of a terminal experimental protocol, blue dye was injected into each 
cannula position to visualise where ketamine would have been injected locally. Injected dye 
remained local to the area of interest, which confirms that there is minimal (if any) leakage of 
locally injected substances (figure 3.11). This confirms that any changes to gamma power or 
correlation would affect only the area of injection. 
Figure 3.11| Local injection of dye remained in the desired injection area. a – Image of rat brain 
injected with dye in positions where cannula were placed for local ketamine injection: PFC – 
prefrontal cortex, VC – visual cortex, Hip – hippocampus indicate injection sites. b – Image of 
hippocampal slice taken from brain in a showing injection of dye remained within the CA1 layer of 
the hippocampus following injection. Both images indicate that ketamine when injected locally 
remained within and only affected the area of interest 
 
Injection of TTX was also used to validate local injection sites and the local injection 
protocol. TTX is a potent neurotoxin which acts by blocking sodium channels on neurons, thus 
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blocking action potential firing. Therefore, sufficient delivery to a neural area of interest 
should decrease oscillatory activity to a level not much above 0 µV. In five rats, 1 µl of 10 ng/ml 
TTX was injected into each local site in sequence, using the same protocol as was used for 
local ketamine injections, whilst recording neural oscillations. In all cases, TTX caused gamma 
to decrease to a level well below baseline recordings (figure 3.12). Furthermore, oscillatory 
activity in other frequency bands never recovered to baseline values in the injected area but 
remained unaffected in other recording areas. This demonstrated that the method of delivery 
used for local ketamine injection was successful, that the drug was delivered only locally and 
that results for local ketamine injection could be treated as reliable.  
Figure 3.12| Local injection of TTX abolished local oscillatory activity in Hip following Hip 
injection. 1 µl of 10 ng/ml TTX was locally injected into Hip at a rate of 0.333 µl/min. Figure shows 
example effects: Top trace shows LFGP in Hip, bottom trace shows all local oscillatory activity in 
Hip. Entire length of trace is 5200 s, injection start point is indicated; before this start point can be 
considered as baseline. After around 2000 s LFGP is reduced to approximately 26 µV2.  
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3iv | Comparison of systemic and local injection of ketamine 
Local injection of ketamine had a different signature of effect than systemic ketamine 
 Average power spectra following ketamine treatment were generated and then 
normalised to baseline power to show changes in the distribution of all oscillation frequencies. 
These spectra revealed a different signature of change in local application vs systemic (figure 
3.13). After local injection of ketamine, there was a broad peak increase covering the start of 
low frequency gamma that is not apparent following systemic ketamine treatment. The 
spectrum for systemic ketamine shows an increase in power across a wider range of 
frequencies than for local ketamine, encompassing the entire gamma range. However, higher 
frequency power (>120 Hz) is reduced after systemic ketamine injection whereas it is 
unchanged following local injection. A large peak in low frequency power is also apparent in 
the spectrum for systemic ketamine yet not in the spectra for local application, indicating that 
lower frequency oscillations such as theta may be altered by systemic ketamine treatment but 
not by local ketamine injection. 
Figure 3.13| Systemic injection of ketamine produced a different effect signature to local 
injection. Average normalised power spectra [n=5] generated from Hip recordings after local (grey 
line) and systemic (black line) ketamine injection. The area of injection for the local spectrum 
shown was also Hip.  
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 The fact that the two different methods of ketamine application showed two different 
spectral effect signatures indicates that the way in which gamma power is changed is also 
different.  Systemic ketamine caused a shift from higher frequency oscillations to increase 
power across the entire gamma range, whereas local ketamine caused a shift from lower 
frequency oscillations to increase power overlapping the lower end of LFG. After local 
ketamine injection, the gamma range was not much affected above 50 Hz and higher 
frequency oscillations were unaffected. 
 
Local application of ketamine to deep brain structures increased gamma power 
 Due to local application of ketamine in VC, Hip and PFC being unable to elicit an 
increase in gamma power comparable to that obtained with systemic ketamine treatment, 
deeper brain structures were proposed as an alternative site of effect. The protocol for 
delivery of ketamine and analysis of data was the same as that for local applications described 
previously. Results presented here are for two rats only and act as a preliminary grounding for 
the theory that it is the action of ketamine on deeper brain structures that elicits the majority 
of changes in gamma power and not action on local circuits in the area of elicited change.  
 1 µl of 5 µg/µl ketamine was injected over 3 minutes into deep brain structures known 
to have neuromodulatory effect in the brain. The most effective site found for increase in 
gamma power after local ketamine injection was the nucleus basalis (NB). As this data is from 
an experiment using only two rats, no statistical analysis is available to determine significance 
and full data analysis has not yet been completed. However, the signature effect following 
ketamine NB injection (figure 3.14) resembles more that seen for systemic treatment as 
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opposed to local area injection (see figure 3.13), with an increase in power occurring across 
the whole of the gamma range. These initial results for NB injection are promising and 
increasing n number for these deeper brain structure injections may elude to the local site of 
action of ketamine in the brain. 
Figure 3.14| Local injection of ketamine into nucleus basalis caused an increase in power across 
the entire gamma range. Signature average power spectrum generated from Hip recordings 
following injection of ketamine into NB [n=2].  Dashed lines depict the gamma range (30-120 Hz) 
in which an increase in average power occurred. Data for power was normalised to baseline values 
before averaging.  
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- DISCUSSION - 
 
4i | Acute PCP model of schizophrenia in freely moving rats 
PCP caused a decrease in percentage correct performance in the sPAL task used, 
indicating that the acute PCP model reproduces deficits in associative learning known to effect 
schizophrenia sufferers (Serra et al, 2001). It could be argued that PCP, as a dissociative agent, 
was impairing the rats’ ability to actually complete the task, rather than actually effecting 
associative learning – which would result in decreased performance. Indeed, behavioural 
changes such as ataxia did occur in the first 60 minutes following PCP injection. However, after 
this time point behavioural effects of PCP had alleviated and even during the time when ataxia 
was present, rats still carried out the task – which was shown by there being no significant 
change in trial number when compared to controls. In a recent study which profiled current 
NMDAR antagonist models of schizophrenia (Talpos et al, 2014), it was also found that 
systemic PCP significantly altered percentage correct in a PAL task without altering trial 
number. Both of these findings show that rats are not physically impaired in task completion 
but that it is an induced cognitive impairment in associative learning that causes decreased 
task performance. As well as decreased percentage correct, rats also showed a decreased 
ability to respond appropriately to correction trials, often continuing to choose the incorrect 
image that had been chosen previously.  This deficit in feedback learning has been shown to 
consistently occur in schizophrenia patients when compared to matched controls (Yilmaz et 
al, 2012). Being unable to correct a wrong decision during task completion is indicative of a 
deficit in working memory, as stated earlier this has been found many times in humans at all 
stages of schizophrenia development. Taken collectively, these results suggest that the PCP 
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rat model of schizophrenia used in this study is a suitable experimental recreation of some of 
the cognitive deficits observed in schizophrenics. 
 Systemic injection of 1 mg/kg PCP in freely moving awake rats caused a significant 
increase in gamma power. As mentioned in the results section, changes recorded in gamma 
power outlasted any behavioural changes induced by PCP - further validating that changes 
occurring at a neuronal level were the key reason for decreased task performance. Also in 
support of this, it has been shown that treatment with ketamine and MK-801 – which block 
NMDARs via non-competitive binding at the same site as PCP, cause an increase in gamma 
activity that is unrelated to behavioural changes such as ataxia (Hakami et al, 2009). Gamma 
power is consistently implicated in cognition and is particularly prevalent during completion 
of mental tasks (Fitzgibbon et al, 2004). As gamma is associated with shifting the cortex to an 
attentive awake state, it would be logical to think that increased gamma power should 
increase attention and induce a higher cognitive state. However, in this study and in many 
previous studies, it has been found that increased gamma activity correlates with poor 
performance in cognitive tasks (Basar-Eroglu et al, 2007). This makes it more likely that it is 
the inter-area synchronisation of gamma that is relevant in cognition. Indeed, inter-area 
synchronisation within the gamma band is known to be abnormal in schizophrenia patients 
(Uhlhaas & Singer, 2010). In this study, cross-correlation analysis was used to determine 
changes in synchronisation between recording areas. Following systemic PCP treatment, the 
most significant decrease in maximum correlation occurred between the hippocampus and 
the prefrontal cortex. The hippocampus is known to be responsible for associating an object 
and its location (Rolls, 1996) whereas the prefrontal cortex is known to be involved in working 
memory and coordination of goal orientated behaviours (Basar-Eroglu et al, 2007; Miller & 
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Cohen, 2001). Therefore, it is feasible that reduced synchronisation between these two areas 
will result in disrupted communication between two vital areas for sPAL completion. It is likely 
that in schizophrenia patients, inefficient communication between neural areas is a significant 
contributor to poor performance in working memory tasks compared to healthy control 
individuals.  
 
4ii | Systemic ketamine model of schizophrenia in terminally anaesthetised rats 
 Terminally anaesthetised rats were used in these experiments to study the effects of 
local ketamine application in vivo and also allowed systemic NMDAR antagonism to be 
conducted without movement artefacts. The stimulation used during terminal experiments 
was successful in shifting the cortex from an unstable ‘sleep-like’ state containing mainly slow 
wave activity to a state that was more relatable to that recorded in awake animals, containing 
regular gamma activity and reduced slow wave. It is extremely important to have a stable 
baseline for experimentation and also to make experimental procedures as relevant as 
possible; by creating this recording situation, initial measurements for gamma activity 
following ketamine injection could be deemed reliable. However, following systemic ketamine 
injection in some rats, small amounts of slow wave activity appeared to return in all recording 
channels. This could be indicative of the effect of the stimulus wearing off somewhat – i.e. the 
stimulus no longer being sufficient in activating the cortex. However, this occurred at least 30 
minutes after injection and following ketamine washout the stimulus worked as well as 
previously.  Therefore, this could be a secondary effect of ketamine itself. More work may 
need to be done on analysis of changes in the lower frequency oscillatory bands following 
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systemic ketamine injection and on further validation of the stimulus strength/position used 
for activating the cortex. Despite this, electrical stimulation of the cortex via deep brain 
structures appears to be a promising method of creating a stable baseline for terminal in vivo 
experiments in rats following further development.  
 As expected, 10 mg/kg ketamine caused a larger increase in gamma power in all 
recording areas than 4 mg/kg when given systemically. However, PrL and Cg1 were the 
greatest affected channels under both doses. This implies that ketamine, when given 
systemically, has the greatest effect in the prefrontal cortex irrespective of dose. As there are 
questions over whether the ketamine model of schizophrenia is recreating cognitive deficits 
or whether it is simply causing hallucinogenic effects (i.e. recreating positive symptoms), it is 
interesting to note that the visual cortex was the least affected area in terms of gamma power 
even under a high dose of ketamine. Comparing the normalised power increase between 
systemic PCP and ketamine injections, it appears that 1 mg/kg PCP in awake rats causes a 
change comparable to somewhere between the two doses of ketamine used in anaesthetised 
rats. Also, the order of channel increase under PCP influence is slightly different to that of 
ketamine. Cg1 showed the largest increase in gamma power following PCP injection, whereas 
PrL showed the smallest. The increase in gamma power in the visual cortex following 1 mg/kg 
PCP injection was of a similar magnitude to that following 10 mg/kg ketamine injection, this 
implies that systemic PCP has a greater effect on the local circuitry of the visual cortex than 
ketamine does. This may translate to a better manifestation of positive symptoms when using 
the PCP model of schizophrenia compared to the ketamine model. However, it should be 
noted that the rats used for ketamine experiments would have had very little sensory input to 
the visual system compared to the rats completing sPAL under PCP.  
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Unfortunately data for HFG range recorded in the freely moving PCP experiments 
could not be obtained as there were many artefacts contained in the range that, when 
removed, left very little reliable trace for analysis. This is most likely due to noise created by 
the recording environment of the testing chamber. As the chamber itself is undergoing 
development by the manufacturer, it would be desirable for this to be eliminated for future 
experiments and reliable HFG data obtained to complement the HFG data from terminal 
experiments in this study. Following systemic ketamine treatment, inter-area HFG correlation 
was decreased except for between the visual cortex and hippocampus. This indicates that 
communication between areas furthest apart in the brain is most disrupted by systemic 
ketamine treatment, and that communication between areas that overlap spatially may 
actually be enhanced. An increase in synchronisation between the visual cortex and 
hippocampus may also be the reason for dissociative effects induced by ketamine in humans, 
as spatial awareness of a perceived visual perception (hallucinations) could be being facilitated 
by this enhanced inter-area communication. The effects of ketamine on HFG (80-120 Hz) are 
relatively understudied in the literature. Systemic ketamine treatment induced significant 
decreases in inter-area HFG correlation whereas no significant changes were found for inter-
area correlations in LFG. Also, significant changes to slow-LFGP inter-area correlations were 
induced by systemic ketamine but inter-area slow-HFGP synchrony was relatively unchanged. 
These findings highlight the need for studies to incorporate an extended gamma range, 
encompassing 30-120 Hz. Support for the inclusion of HFG in experimental analysis has also 
been concluded previously elsewhere in the literature (Grutzner et al, 2013).  
It may be desirable to expand on the systemic ketamine data obtained in this study by 
increasing the n number of the 10 mg/kg cohort to the same as that used for 4 mg/kg. This 
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would allow reliable cross-correlation analysis for 10 mg/kg ketamine and comparison 
between the two doses. As 10 mg/kg caused greater increases in gamma power, it would be 
expected that this dose would have also caused more significant changes to cross-
correlations. Work from previous studies suggests that the minimum systemic dose of 
ketamine required to produce cognitive deficits comparable to schizophrenia is 5 mg/kg 
(Kocsis et al, 2013), reinforcing the idea that greater changes in inter-area cross-correlation 
would occur if a higher dose were used.  
 
4iii| Local application of ketamine in terminally anaesthetised rats 
 As far as the author is aware, this is the first time local application of ketamine in vivo 
has been conducted whilst recording local EEG activity in the same area. The protocol used 
for local injection into the visual cortex, prefrontal cortex and hippocampus was deemed 
successful due to vehicle injections causing no change in local oscillations but injection of TTX 
abolishing almost all recorded activity in the injected area without affecting other recording 
areas.  
No significant changes to gamma power were found following local injection of 5 µg/µl 
ketamine. As mentioned in results, data from one rat for local hippocampal injection altered 
the average peak gamma value which resulted in apparent substantial percentage increases 
in gamma power. As stated these data were not deemed statistical outliers however removing 
them from the data set dramatically alters the average percentage increase. When the data 
for this rat is removed from the calculation for average percentage change in gamma power 
following local hip injection the new values are as follows; VC: +5%, Cg1: -5%, PrL: -6%, Hip: 
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+8%. These new values reinforce the conclusion that no substantial change to gamma power 
was elicited following local ketamine treatment. Increasing the n number for local ketamine 
injection would confirm whether the response elicited in this one rat is indeed not typical and 
would limit the effect of this data on the final average values.  
Taking these results collectively, it can be concluded that increased local gamma power 
in the recorded areas induced by systemic ketamine treatment was not generated by local 
ketamine binding in those areas. This is contrary to much of the literature, where many groups 
have assumed that ketamine has a direct effect on local neural circuitry. However, it should 
be noted that the majority of support for this concept comes from in vitro studies in which 
application of ketamine has been used on isolated local circuits. But there is still some dispute 
even amongst in vitro studies as to whether ketamine acts directly on local circuitry to 
modulate change. For example, ketamine has been found to have direct local effects on 
hippocampal preparations (Greene, 2001), but it has also been found not to have any affect 
at all in this area in other experiments (Roopun et al, 2008). Roopun et al also found that 
ketamine altered oscillatory activity in in vitro preparations from the auditory cortex despite 
being ineffective in hippocampal slices. This may mean that ketamine has varying local effects 
dependent on the area of application. Although it is currently difficult to identify the direct 
cause of increased gamma activity using in vivo experiments, this study highlights it is not 
conclusive that ketamine primarily acts locally in the area of interest to increase gamma 
oscillations.  
It has been previously commented that there is much inconsistency between in vivo 
and in vitro experiments with regards to evoked gamma activity following ketamine treatment 
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and that conclusions from in vitro studies should not be made in isolation (Kocsis et al, 2013). 
Whilst useful experiments, in vitro electrophysiology studies may be over-simplifying what 
actually occurs in the brain following ketamine treatment. This could be due to the loss of 
afferent connections that occurs during slice preparation for in vitro studies. In line with this, 
in vivo studies should be deemed more valid when considering the implications of results with 
respect to schizophrenia. One in vivo study did find that local application of an NMDAR 
antagonist to the prefrontal cortex in freely moving rats was sufficient to induce stereotypic 
behavioural changes, local changes in oscillatory activity and increase c-fos expression in 
cortical areas – which is a biomarker for neuronal activity (Nowak et al, 2012). However, the 
authors used MK-801 - a more potent NMDAR antagonist than ketamine. Also, the dose of 
MK-801 that was deemed sufficient to achieve this was 4 µg/µl; given the higher binding 
affinity of MK-801 to the NMDAR, perhaps this indicates that a local dose of 5 µg/µl ketamine 
is not sufficient to induce oscillatory changes. Further experiments using local application of a 
higher ketamine dose could be undertaken to validate this. Alternatively, injection of MK-801 
into the visual cortex and hippocampus, as well as the prefrontal cortex, could be undertaken 
in future experiments to observe the local effects on gamma activity of a more selective 
NMDAR antagonist. This would further elucidate whether selective local NMDAR antagonism 
affects local generation of gamma oscillations.  
As well as changes to recorded power within the gamma band, it was expected that - 
should ketamine be acting primarily at the local circuit level, the effect signature would be 
similar to that of systemic ketamine. This was not the case following local injection of ketamine 
in the hippocampus – the area where the clearest change in gamma power was induced (albeit 
not significant). Systemic ketamine caused a broad increase across the entire gamma range 
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accompanied by a decrease in higher frequency oscillations, whereas local ketamine caused a 
decrease in lower frequency oscillations and a peak increase encompassing the lower end of 
LFG without altering higher frequency oscillations.  This again indicates that ketamine does 
not act locally in the same manner in which it does systemically and it is therefore unlikely 
that ketamine is acting locally in the recorded areas to produce significant changes observed 
following systemic ketamine injection. 
The nucleus basalis consists of cholinergic neurons that project to the cortex and 
ablation studies have previously implicated this are in the control of cognition (Wenk, 1997). 
Therefore it is feasible that projections from the nucleus may be able to alter oscillatory 
activity in local neural networks. Preliminary results from injection into the nucleus basalis 
showed a modest broad increase in power across the entire gamma range – not dissimilar to 
that induced by systemic ketamine. In light of this, it is much more likely that ketamine is 
acting locally on neuromodulatory systems (such as the nucleus basalis) to elicit the increases 
in gamma power observed following systemic injection. It could be that simultaneous binding 
of ketamine to several deep brain structures has a synergistic effect on increasing gamma 
power. Of course, at this point in time these comments are rather speculative and future 
studies will need to be conducted on local applications to deep brain structures to firstly, 
increase the n number for nucleus basalis data and secondly, to examine other injection areas. 
It is clear from the results of this study that much more work is required to characterise local 
activity of ketamine in the brain using in vivo animal models.  
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4iv| Concluding remarks 
 It has been shown that systemic treatment with both PCP and ketamine is sufficient in 
eliciting a significant increase in gamma power in the visual cortex, prefrontal cortex and 
hippocampus whilst decreasing synchronisation between these areas – further validating the 
use of NMDAR antagonists in modelling schizophrenia in rats. However, this study provides 
evidence to suggest that these drugs are not acting on the local neural networks in these 
recorded areas in order to effect gamma. Local application to neuromodulatory nuclei appears 
to be a promising target for elucidating the effects of local NMDAR antagonism on gamma 
activity and this is the recommended focus for future experiments. If key local sites were 
identified that significantly impacted on gamma activity, it would be desirable to utilise these 
for ketamine/PCP injection during behavioural experiments such as those used in systemic 
PCP application in this study. Also, it would be useful for more work to be done on validating 
the local dose of ketamine needed to induce a significant oscillatory change, or the relative 
dose of ketamine that occurs in neural regions following systemic injection - as knowledge of 
this is not abundant in the literature. 
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